| First Author | Dahan R | Year | 2015 |
| Journal | Cancer Cell | Volume | 28 |
| Issue | 3 | Pages | 285-95 |
| PubMed ID | 26373277 | Mgi Jnum | J:225951 |
| Mgi Id | MGI:5695381 | Doi | 10.1016/j.ccell.2015.08.004 |
| Citation | Dahan R, et al. (2015) FcgammaRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell 28(3):285-95 |
| abstractText | Immune checkpoint blockade of the programmed cell death protein 1 (PD-1) pathway by monoclonal antibodies (Abs) has shown promising clinical benefit in the treatment of multiple cancer types. We elucidated the contribution of the fragment crystallizable (Fc) domains of anti-PD-1 and anti-PD-ligand 1 (L1) Abs for their optimal anti-tumor activity. We revealed that distinct Fcgamma receptor (FcgammaRs) dependency and mechanisms account for the in vivo activity of anti-PD-1 versus anti-PD-L1 Abs. Anti-PD-1 Abs were found to be FcgammaR independent in vivo; the presence of FcgammaR-binding capacity compromises their anti-tumor activity. In contrast, the anti-PD-L1 Abs show augmented anti-tumor activity when activating FcgammaR binding is introduced into the molecules, altering myeloid subsets within the tumor microenvironment. |
